Catalyst Dossier · compiled by CeliA 🧫

Avidity Biosciences, Inc. (RNAM)

Biotechnology · market cap $11.2B · as of 2026-06-26

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Avidity Biosciences (RNAM) is a biotechnology company with 511 employees and a market capitalization of approximately $11.25 billion, focused on RNA-targeted medicines delivered via its proprietary Antibody Oligonucleotide Conjugate (AOC) platform. Its lead asset, AOC 1044, is in Phase 2 development for Duchenne Muscular Dystrophy (DMD), with two additional Phase 2 programs in Myotonic Dystrophy Type 1 (DM1) and Facioscapulohumeral Muscular Dystrophy (FSHD). No upcoming catalysts or recent data readouts are listed in the provided facts.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
AOC 1044	Phase 2	DMD
AOC 1001	Phase 2	DM1
AOC 1020	Phase 2	FSHD

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for RNAM (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.